The other group at the highest risk when it comes to RSV is children under age five, and specifically infants—especially ...

Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years ...

GSK has received Canadian approval for its respiratory syncytial virus vaccine in adults between 50 and 59, the company said ...

Researchers found that vaccine effectiveness was 80% and 81% against RSV-associated hospitalizations and against RSV-associated critical illness among 28,271 hospitalizations for RSV-like illness ...

Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years ...

Q3 results confirms that the U.S. vaccine market for respiratory syncytial virus (RSV), led by Pfizer (PFE) and GSK (GSK), is ...

The respiratory virus is the leading cause of hospitalisation for infants, with 12,000 babies admitted each year. Before next ...

The company says it expects the RSV vaccine — called mRESVIA — to be available in early 2025. There are two other vaccines ...

In 2025, eligible pregnant women will be able to receive the respiratory syncytial virus (RSV) vaccine for free under the ...

In three months, the distribution of RSV vaccines will begin in the Americas, according to a PAHO announcement.

GSK has received approval for its vaccine, AREXVY, in Canada to prevent LRTD caused by RSV in adults aged 50 to 59 years.

WAUSAU, Wis. (WSAW) --- Doctors recommend that people learn about the RSV vaccine as cold and flu season approaches Wisconsin. RSV, or Respiratory Syncytial Virus, is a common contagious virus that ...